Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached
by multidisciplinary teams in high specialized centers. Until today no standard of care
exists to treat these cancers. The identification of a target, the androgen receptor, in SG
tumors has allowed for new treatment strategies options for this rare group of diseases. As a
matter of fact, strong positivity for androgen expression has been found in salivary duct
carcinoma and adenocarcinomas. The purpose of this study is therefore to evaluate the
efficacy and safety of chemotherapy versus androgen deprivation therapy (ADT) in patients
with recurrent and/or metastatic AR expressing SGCs.
The study will include two cohorts of patients: Cohort A, which comprises chemo-naïve
patients, and Cohort B, which comprises pretreated patients.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC